Compare · KIDS vs WST
KIDS vs WST
Side-by-side comparison of OrthoPediatrics Corp. (KIDS) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KIDS and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $22.07B, about 53.1x KIDS ($415.9M).
- Over the past year, KIDS is down 25.6% and WST is up 41.7% - WST leads by 67.3 points.
- WST has been more active in the news (4 items in the past 4 weeks vs 3 for KIDS).
- WST has more recent analyst coverage (15 ratings vs 8 for KIDS).
- Company
- OrthoPediatrics Corp.
- West Pharmaceutical Services Inc.
- Price
- $16.16-0.28%
- $306.12-1.10%
- Market cap
- $415.9M
- $22.07B
- 1M return
- -0.40%
- +23.98%
- 1Y return
- -25.64%
- +41.67%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 3
- 4
- Recent ratings
- 8
- 15
OrthoPediatrics Corp.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest KIDS
- SEC Form DEF 14A filed by OrthoPediatrics Corp.
- SEC Form DEFA14A filed by OrthoPediatrics Corp.
- OrthoPediatrics Corp. to Report First Quarter Financial Results on April 30, 2026
- OrthoPediatrics Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- OrthoPediatrics to Participate in the 25th Annual Needham Virtual Healthcare Conference
- COO and CFO Hite Fred was granted 77,405 shares and sold $224,129 worth of shares (12,993 units at $17.25), increasing direct ownership by 30% to 277,477 units (SEC Form 4)
- Pres. Trauma & Def. Correction Hauser Joseph W was granted 65,700 shares and sold $148,281 worth of shares (8,596 units at $17.25), increasing direct ownership by 41% to 194,767 units (SEC Form 4)
- President and CEO Bailey David R sold $336,979 worth of shares (19,535 units at $17.25), decreasing direct ownership by 6% to 298,020 units (SEC Form 4)
- President of Scoliosis Odle Gregory A sold $145,469 worth of shares (8,433 units at $17.25) and was granted 47,380 shares, increasing direct ownership by 26% to 187,735 units (SEC Form 4)
- General Counsel and Secretary Gerritzen Daniel J was granted 47,380 shares and sold $148,592 worth of shares (8,614 units at $17.25), increasing direct ownership by 35% to 149,533 units (SEC Form 4)
Latest WST
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Reports First-Quarter 2026 Results
- West to Host First-Quarter 2026 Conference Call
- SEC Form 4 filed by Haugen Janet Brutschea
- West Expands Dublin Facility to Support High-Volume Injectable Therapies, Including Diabetes and Obesity
- Amendment: SEC Form SCHEDULE 13G/A filed by West Pharmaceutical Services Inc.
- SEC Form DEFA14A filed by West Pharmaceutical Services Inc.
- SEC Form DEF 14A filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits